Skip to main navigation Skip to search Skip to main content

Targeting prostate cancer cells with genetically engineered polypeptide-based micelles displaying gastrin-releasing peptide

  • Wei Zhang
  • , Sanjay Garg
  • , Preethi Eldi
  • , Fiona Huan huan Zhou
  • , Ian R.D. Johnson
  • , Doug A. Brooks
  • , Frankie Lam
  • , Grigori Rychkov
  • , John Hayball
  • , Hugo Albrecht

Research output: Contribution to journal › Article › peer-review

Abstract

In recent years G protein-coupled receptors (GPCRs) have emerged as crucial tumorigenic factors that drive aberrant cancer growth, metastasis and angiogenesis. Consequently, a number of GPCRs are strongly expressed in cancer derived cell lines and tissue samples. Therefore a rational anti-cancer strategy is the design of nano-medicines that specifically target GPCRs to bind and internalise cytotoxic drugs into cancer cells. Herein, we report the genetic engineering of a self-assembling nanoparticle based on elastin-like polypeptide (ELP), which has been fused with gastrin releasing peptide (GRP). These nanoparticles increased intracellular calcium concentrations when added to GRP receptor positive PC-3 prostate cancer cells, demonstrating specific receptor activation. Moreover, GRP-displaying fluorescent labelled nanoparticles showed specific cell-surface interaction with PC-3 prostate cancer cells and increased endocytic uptake. These nanoparticles therefore provide a targeted molecular carrier system for evaluating the delivery of cytotoxic drugs into cancer cells.

Original languageEnglish
Pages (from-to)270-279
Number of pages10
JournalInternational Journal of Pharmaceutics
Volume513
Issue number1-2
DOIs
Publication statusPublished or Issued - 20 Nov 2016

Keywords

  • Elastin-like polypeptide (ELP)
  • G protein-coupled receptors (GPCRs)
  • Gastrin releasing peptide (GRP)
  • Micelle
  • Prostate cancer

ASJC Scopus subject areas

  • Pharmaceutical Science

Cite this